178 related articles for article (PubMed ID: 32594779)
1. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults.
Wang J; Niu S; Dong W; Wei L; Ou L; Zhang T; Zhang L; Nie X; Wang Q; Shen T; Wang Q; Xia L; Liu G; Jin J; Zheng Q; Song H; Fang Y
Expert Opin Investig Drugs; 2020 Jul; 29(7):755-762. PubMed ID: 32594779
[TBL] [Abstract][Full Text] [Related]
2. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers.
Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Clinical Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of GB221 Injection and Trastuzumab (Herceptin
Zhu Y; Li C; Chen L; Liu H; Ou L; Li T; Wang X; Wang T; Tian J; Liang X; Hu Z; Zhan Y; Xiao S; Wang X; Li Y; He J; Zheng Q; Song H; Li X; Fang Y
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):383-392. PubMed ID: 38564097
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
[TBL] [Abstract][Full Text] [Related]
5. TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin
Demarchi M; Coliat P; Mclendon K; Chung Shii Hii J; Feyaerts P; Ang F; Jaison L; Deforce F; Derde MP; Kim MJ; Park LS; Detappe A; Pivot X
Pharmacol Res Perspect; 2021 Aug; 9(4):e00839. PubMed ID: 34309241
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects.
Zhu X; Ding Y; Yu Y; Wang M; Zhou W; Wang J; Zhu X; Zhang H; Wang M; Chai K; Zhang X; Luk A; Jiang W; Liu S; Zhang Q
Cancer Chemother Pharmacol; 2021 Mar; 87(3):349-359. PubMed ID: 33169186
[TBL] [Abstract][Full Text] [Related]
7. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ
Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects.
Farmahini Farahani M; Maghzi P; Jafari Aryan N; Payandemehr B; Soni M; Azhdarzadeh M
Expert Opin Investig Drugs; 2020 Dec; 29(12):1443-1450. PubMed ID: 33016783
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin
Lickliter JD; Dadhania RN; Trivedi RK; Naveen Kumar SR; Reddy PK
Indian J Med Res; 2021 Mar; 154(3):509-519. PubMed ID: 35142643
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X
Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
Singh I; Patel R; Patel A; Jose V
Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
[TBL] [Abstract][Full Text] [Related]
13. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial.
Morita J; Tanaka M; Nomoto M; Matsuki S; Tsuru T; Matsuguma K; Shiramoto M
BioDrugs; 2016 Feb; 30(1):17-25. PubMed ID: 26691837
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men.
Zhang H; Liu T; Wu M; Wei H; Li C; Li X; Liu J; Chen H; Ding Y; Liu L
Expert Opin Biol Ther; 2022 Feb; 22(2):179-186. PubMed ID: 33616478
[TBL] [Abstract][Full Text] [Related]
16. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
[TBL] [Abstract][Full Text] [Related]
17. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
Alexeev SM; Khorinko AV; Mukhametshina GZ; Shelepen KG; Burdaeva ON; Kulik SA; Satheesh CT; Srivastava K; Vikranth M; Kryukov F; Paltusova AN; Shustova MS; Ivanov RA
BMC Cancer; 2020 Aug; 20(1):783. PubMed ID: 32819305
[TBL] [Abstract][Full Text] [Related]
18. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
Hanes V; Chow V; Pan Z; Markus R
Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275
[TBL] [Abstract][Full Text] [Related]
19. A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar.
Wang Y; Liu Z; Deng Q; Su Z; Xue J; Zhao Y; Yang H
Expert Opin Drug Metab Toxicol; 2023; 19(11):849-855. PubMed ID: 37526387
[TBL] [Abstract][Full Text] [Related]
20. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
